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In the present study, we investigated the ex vivo expansion of human adipose tissue–derived mesenchymal
stromal cells (ATSCs) to identify factors that promoted efficient expansion while preserving stem cell potential. We
examined several growth factors and steroids, and found that the combination of a low concentration of fibroblast
growth factor-2 (FGF-2) (1 ng=mL) and dexamethasone (DEX) or betamethasone (BET) enhanced the proliferation
of ATSCs by approximately 30–60% as compared to control. Enhanced proliferation under these conditions was
confirmed using ATSCs isolated from three independent donors. ATSCs that were expanded in the presence of
FGF-2 and DEX for 5 days were capable of differentiating into either osteoblastic or adipogenic cells, and the cells
were positive for the mesenchymal stem cell markers such as CD29, CD44, CD90, CD105, and CD146, suggesting
that the stem cell potential of the ATSCs was preserved. Analysis of signaling pathway revealed that tyrosine
phosphorylation of Src kinase was dramatically increased in response to FGF-2 and DEX, suggesting the in-
volvement of Src-dependent pathways in the stimulatory mechanism of proliferation of ATSCs by FGF-2 and
DEX. Moreover, Src family kinase inhibitors (SU6656 and Src kinase inhibitor I) substantially reduced the FGF-2
and DEX–induced proliferation of ATSCs. SU6656 also inhibited the osteogenic and adipogenic differentiation of
ATSCs. The results of the current study demonstrate that FGF-2 in combination with DEX stimulates the prolif-
eration and osteoblastic and adipogenic differentiation of ATSCs through a Src-dependent mechanism, and that
FGF-2 and DEX promote the efficient ex vivo expansion of ATSCs.
Introduction
Tissue engineering using mesenchymal stem cells(MSCs) is a promising technology for the treatment or
regeneration of tissue defects. MSCs have been identified in a
variety of tissues, including adipose tissue.1–3 Adipose tissue
is a valuable source of MSCs because it is abundant and can
be obtained with little surgical difficulty. Under the appro-
priate conditions, MSCs derived from adipose tissue are
capable of differentiating into adipogenic, chondrogenic, myo-
genic, and osteogenic cells.4 The cell surface expression of
MSC markers on adipose tissue–derived mesenchymal
stromal cells (ATSCs) is similar to that of bone marrow–
derived mesenchymal stem cells (BMSCs).5 Moreover,
ATSCs are similar to BMSCs in their potential to differentiate
into osteoblasts in vitro and to synthesize bone in vivo.6
ATSCs, in combination with recombinant bone morphoge-
netic proteins, have been shown to induce bone formation in
vivo and promote healing of a critically sized femoral defect
in an athymic rat.7 These results indicate that ATSCs are a
viable alternative source of stem cells for bone regeneration.
However, to obtain reasonable numbers of ATSCs for tissue
engineering applications—in particular, the regeneration of
large lesions—ex vivo expansion of ATSCs will be required.
Several growth factors have been implicated in the regu-
lation of MSC proliferation. In particular, fibroblast growth
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factors (FGFs) regulate multiple biological processes, includ-
ing bone and cartilage formation.8 The effect of FGF-2 on MSC
proliferation varies, and depends largely on the stage of dif-
ferentiation of the MSCs.9–11 Similarly, variable effects of FGF-
2 on the osteoblastic differentiation of BMSCs have also been
reported. FGF-2 significantly increases the proliferation of
ATSCs and enhances chondrogenesis in a three-dimensional
micromass culture.12 However, FGF-2 also reportedly inhibits
osteogenesis in mouse ATSCs and sustains their proliferative
and osteogenic potential.13 Recently, FGF-2 has been shown to
maintain the self-renewing state human ATSCs.14
Steroids can regulate multiple biological processes, in-
cluding bone formation. Dexamethasone (DEX), a synthetic
corticosteroid, is a potent modulator of the osteogenic dif-
ferentiation of MSCs. DEX supports osteogenic lineage dif-
ferentiation15–17 by binding to specific regulatory proteins
and activating the transcription of osteoblast-specific genes.
DEX increases alkaline phosphatase (ALP) activity, which
is required for matrix mineralization.16 The combination of
FGF and DEX induces more profound effects on the osteo-
blastic differentiation of MSCs derived from bone marrow.
For example, FGF-2 in combination with DEX increases the
colony size and DNA content of human BMSCs as compared
to FGF-2 alone. However, the underlying molecular mecha-
nism of action of the two factors is unknown.18–20 BMSCs
that are expanded in the presence of FGF-2 and DEX stim-
ulate bone formation in nude mice.20 In some cases, such as
with rat marrow stromal cells, treatment with FGF-2 and
DEX decreases DNA content as compared to FGF-2 alone.21
In the present study, we developed an efficient method for
the ex vivo expansion of ATSCs using FGF-2 in combination
with steroids, and showed that ATSCs that are expanded in
the presence of FGF-2 and DEX maintain their multi-lineage
potential. We also investigated the stimulatory mechanism of
proliferation of ATSCs by FGF-2 and DEX.
Materials and Methods
Isolation and culture of ATSCs
Fat tissue was obtained from patients undergoing total hip
replacement surgery. Informed consent was obtained from
the patients before surgery. Fat tissue was minced with a
scalpel and washed with phosphate buffered saline (pH 7.4)
to remove contaminating blood, and then digested with col-
lagenase type I 2 mg=mL (Warthington Biochemical, Lake-
wood, NJ) for 45 min at 378C with constant agitation. Enzyme
activity was neutralized by the addition of a-modified Eagle’s
medium (a-MEM) (Gibco BRL, Gaithersburg, MD) containing
10% fetal bovine serum (FBS) (Biowhittaker, Walkersville,
MD). Cells were obtained by centrifugation at 1200 g for
10 min. Cell pellets were resuspended in a-MEM and fil-
tered through a 250-mm nylon mesh to remove debris. The
filtered cell suspension was incubated with a-MEM supple-
mented with 10% FBS for 24 h. After incubation, nonadherent
cells were removed, and adherent cells, comprised of ATSCs,
were cultured and expanded for further analysis. ATSCs that
were passaged less than three were used for all experiments.
The culture medium was changed every other day.
Analysis of ATSC proliferation
ATSCs were seeded into 96-well plates at a density of 700
cells=well. Cells were treated with the indicated concentrations
of FGF-2 (R&D Systems, Minneapolis, MN), betamethasone
(BET), DEX, hydrocortisone (HYD), prednisolone (PRE)
(Sigma, St. Louis, MO), or a combination of FGF-2 and steroid
for 3, 5, or 7 days. Proliferation was measured using a pro-
liferation assay kit (Promega, Madison, WI), according to
manufacturer’s instructions. Optical density at 490 nm was
measured with an ELISA plate reader (BioRad, Hercules, CA).
Cell number was obtained using a hemocytometer.
Flow cytometric analysis
ATSCs were incubated with FGF-2 and DEX in a-MEM
supplemented with 10% FBS for 5 days. Cells were harvested
with 0.25% trypsin=EDTA and incubated in 1% bovine serum
albumin (BSA) containing 100 mL of a solution of monoclonal
antibody directed against CD29, CD44, CD90, CD105, CD146,
or CD34 (BD Pharmingen, Palo Alto, CA) for 30 min at 48C.
The cells were centrifuged at 1200 g for 5 min and then
washed with 1% BSA. The resuspended cells were fixed for
30 min in ice-cold 4% formaldehyde. After fixation, the
cells were washed with 1% BSA, and then analyzed using
a FACSAria Sorting Flow Cytometer (Beckton Dickinson,
Franklin Lakes, NJ).
Multilineage differentiation of ATSCs
ATSCs that were expanded in the presence of FGF-2 and
DEX for 5 days were replated into 48-well plates at a density
of 1104 cells=well. On the following day, osteoblastic dif-
ferentiation was induced by treatment with osteogenic me-
dium (a-MEM supplemented with 10% FBS, 50mg=mL
a-ascorbic acid, 10 mM b-glycerophosphate, and 10 nM DEX)
for 14 days. Osteoblastic differentiation was assessed using
alizarin red S (AR-S) staining. AR-S deposits were recovered
by incubating the cells in a solution of 10% cetylpyridinium
chloride (Sigma) in 10 mM sodium phosphate (pH 7.0) for














































































FIG. 1. Induction of proliferation of adipose tissue-derived
mesenchymal stromal cells (ATSCs) by fibroblast growth
factor-2 (FGF-2) and steroids. ATSCs were cultured in the
presence of FGF-2 (1 ng=mL) and the indicated concentra-
tions of steroid (BET, DEX, HYD, and PRE) for 7 days. Pro-
liferation assays were performed as described in Materials
and Methods. *p< 0.05 as compared to untreated control cells.
BET, betamethasone; DEX, dexamethasone; HYD, hydro-
cortisone; PRE, prednisolone; OD, optical density.
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determined by measuring absorbance at 570 nm. Adipogenic
differentiation was induced by treatment with adipogenic
medium (a-MEM supplemented with 10% FBS, 1mM DEX,
111 mg=mL isobutylmethylxanthine, 0.2 mM indomethacin,
and 10 mg=mL insulin) for 14 days. Adipogenesis was as-
sessed using Oil red O staining. To obtain quantitative data,
300 mL of isopropyl alcohol was added to the stained cells,
and the amount of extracted dye was determined by absor-
bance at 540 nm using an ELISA plate reader.
Western blot analysis
Total cell lysate was prepared in RIPA buffer (50 mM Tris,
pH 7.4, 1% NP-40, 150 mM NaCl, 1 mM EDTA, 1 mM PMSF,
1 mM Na3VO4, 1 mM NaF, pepstatin 1 g=mL, and aprotinin
1 g=mL), and equal amounts of protein (20 mg) were sepa-
rated by 8% SDS-PAGE. Proteins were transferred to a ni-
trocellulose membrane. The membrane was incubated in a
solution of 5% skim milk in Tris buffered saline containing
Tween-20 (20 mM Tris, pH 7.6, 137 mM NaCl, and 0.1%
Tween-20) and then incubated with primary antibodies di-
rected against phosphorylated (phospho)-p38 (BD Pharmin-
gen), phospho-Src, Src (Cell signaling Technology, Danvers,
MA), extracellular signal–regulated kinase (ERK), c-Jun N
terminal kinase ( JNK), or p38 (Santa Cruz, Santa Cruz, CA),
as indicated. The membranes were incubated with per-
oxidase-conjugated secondary anti-mouse or anti-rabbit
immunoglobulin (IgG) (Zymed, South San Francisco, CA),
and immunoreactive proteins were detected using chemilu-
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FIG. 2. Induction of proliferation of ATSCs derived from three independent donors by FGF-2 and DEX. ATSCs were
cultured with FGF-2 (1 ng=mL), DEX (10 nM), or FGF-2 plus DEX for 3, 5, and 7 days. (A) Proliferation assays were carried
out as described in Materials and Methods. Data represent the means standard error (SE) of three independent experiments
(n¼ 3). Proliferation of ATSCs by FGF-2 (1 ng=mL) þ DEX (10 nM) was significantly increased at 5 and 7 days of culture
compared to control (*, p< 0.05). (B) ATSCs were cultured with or without FGF-2 (1 ng=mL) plus DEX (10 nM) for 5 days, and
cell number was measured using a hemocytometer.
Table 1. Expression of MSC Markers on the Surface
of ATSCs Expanded in the Presence of FGF-2, DEX,
or FGF-2 Plus DEX
Marker Control FGF-2 DEX FGF-2þDEX
CD29 97.6 98.2 98.3 98.3
CD44 98.3 98.6 98.0 98.3
CD90 98.0 97.8 97.8 97.0
CD105 99.6 99.7 99.4 99.7
CD146 9.3 8.9 7.3 4.6
CD34 0.7 0.4 0.6 0.4
MSCs, mesenchymal stem cells; ATSCs, adipose tissue-derived
mesenchymal stromal cells; FGF-2, fibroblast growth factor-2; DEX,
dexamethasone.
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Statistical analysis
Statistical analysis was performed using SPSS 11.0. Data
were analyzed using one-way ANOVA, and a Duncan’s
Multiple Range Test was also adapted as a post hoc test. A p-
value of less than 0.05 was considered statistically significant.
Results
Effect of steroids and FGF-2 on the proliferation
of ATSCs
To investigate the effect of steroids alone or in combina-
tion with a low concentration of FGF-2 (1 ng=mL) on the
proliferation of ATSCs, cells were treated with varying
amounts of steroid, with or without FGF-2, for 7 days.
Treatment of ATSCs with 1 or 10 nM BET, DEX, HYD, or
PRE had no obvious stimulatory effect on proliferation.
However, when combined with FGF-2, 1 nM BET or DEX
enhanced optical density (OD) by 29.3% and 30.3%, respec-
tively ( p< 0.05), as compared to control (Fig. 1), indicating
stimulation of the proliferation of ATSCs by these combi-
nations. The stimulatory effect of steroids plus FGF-2 was
greater in the presence of 10 nM BET and DEX (increases of
OD by 62.9% and 61.7%, respectively, p< 0.05) (Fig. 1). The
effect of FGF-2 plus other steroids (HYD and PRE) on the
proliferation of ATSCs was not prominent. These results
suggested that FGF-2 and DEX or BET act in a cooperative
manner to stimulate the proliferation of ATSCs.
Effect of FGF-2 and DEX on the proliferation
of donor-derived ATSCs
To confirm the stimulatory effect of FGF-2 and steroids
on the proliferation of ATSCs, ATSCs were isolated from
FIG. 3. Osteoblastic differentiation of ATSCs expanded in the presence of FGF-2 and DEX. ATSCs were cultured with FGF-2
(1 ng=mL), DEX (10 nM), or FGF-2 plus DEX for 5 days. The expanded cells were reseeded and treated with osteogenic
medium for an additional 14 days to induce osteoblastic differentiation. (A) Calcium deposition was visualized by staining
with alizarin red S (AR-S) solution (original magnification, 40). (B) AR-S was extracted using 10% (w=v) cetylpyridinium
chloride and quantified by absorbance at 570 nm (OD 570 nm). Color images available online at www.liebertonline.com=ten.
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three independent donors and treated with FGF-2 (1 ng=mL),
DEX (10 nM), or FGF-2 plus DEX for 3, 5, or 7 days. Treat-
ment with FGF-2 alone increased the proliferation of ATSCs
by an average of 22% and 20% at days 5 and 7, respectively,
as compared to control, whereas proliferation was increased
by an average of 40% and 36.5% at days 5 and 7, respec-
tively, by FGF-2 plus DEX, as compared to untreated cells
(Fig. 2A). Treatment with FGF-2 plus DEX increased the
proliferation of ATSCs by an average of 14.5% and 13.6% at
days 5 and 7, respectively, as compared to FGF-2 treatment
alone (Fig. 2A). To confirm these results, we carried out an
analysis of cell number. After treatment with FGF-2 and
DEX, the number of ATSCs increased by 81–103% as com-
pared to control (Fig. 2B). These results demonstrated
that combined treatment with low concentrations of FGF-2
and DEX strongly enhances the proliferation of ATSCs
in vitro.
Expression levels of MSC markers in ATSCs
cultured with FGF-2 and DEX
To determine whether ATSCs that were expanded in the
presence of FGF-2 and DEX maintained the expression of
MSC cell surface markers, ATSCs were cultured with FGF-2
and DEX for 5 days, and the expression of CD29, CD44,
CD90, CD105, and CD146 was examined by flow cytometry.
More than 97% of cells that were expanded in the presence of
FGF-2 and DEX were positive for CD29, CD44, CD90, and
CD105, which was similar to untreated ATSCs (Table 1).
However, CD146-positive cells were only between 4.5% and
9.3% (Table 1). This result is consistent with a previous
study, demonstrating that CD146 expression was decreased
during passage.22 Therefore, ATSCs that were expanded
in vitro in the presence of FGF-2 and DEX expressed MSC
markers, including CD29, CD44, CD90, CD105, and CD146.
FIG. 4. Adipogenic differentiation of ATSCs expanded in the presence of FGF-2 and DEX. ATSCs were cultured with FGF-2
(1 ng=mL), DEX (10 nM), or FGF-2 plus DEX for 5 days. The expanded cells were reseeded and treated with adipogenic
medium for an additional 14 days. (A) Oil droplets were visualized by staining with oil red O solution (original magnifi-
cation, 40). (B) Stain was extracted using isopropyl alcohol, and the amount of oil red O was quantified by OD 570 nm. Color
images available online at www.liebertonline.com=ten.
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Effect of FGF-2 and DEX on osteoblastic
and adipogenic differentiation of ATSCs
To determine whether ATSCs cultured in vitro with FGF-2
and DEX maintained their multi-lineage differentiation po-
tential, ATSCs were cultured in the absence (control cells) or
presence of FGF-2 and DEX for 5 days. Expanded cells were
collected, reseeded, and then cultured for an additional 14
days in osteogenic or adipogenic medium. ATSCs that were
first expanded with FGF-2 and DEX were capable of differ-
entiating into either osteoblastic (Fig. 3) or adipogenic cells
(Fig. 4). Of note, ATSCs expanded in the presence of FGF-2
and DEX exhibited increased levels of osteoblastic and adi-
pogenic differentiation as compared to control cells (Figs. 3
and 4). These results indicated that the expansion of ATSCs
in the presence of FGF-2 and DEX maintains their osteogenic
and adipogenic differentiation potential.
Tyrosine phosphorylation of Src kinase
in ATSCs exposed to FGF-2 and DEX
To begin to elucidate the signaling pathways that were
involved in the stimulatory effect of FGF-2 and DEX on the
proliferation of ATSCs, cells were treated with FGF-2 and
DEX for 1, 3, or 5 days, and the level of phosphorylation of
key signaling molecules was examined by Western blot.
Tyrosine phosphorylation of Src kinase was significantly
increased by treatment with FGF-2 and DEX, whereas that of
JNK, p38, and ERK was decreased (Fig. 5). These results
suggested the potential involvement of Src kinase in the
stimulation of proliferation and subsequent osteoblastic dif-
ferentiation of ATSCs by FGF-2 and DEX.
Effect of Src kinase inhibitors on FGF-2
and DEX–induced proliferation of ATSCs
To further examine the involvement of Src or Src family
kinases in the stimulation of proliferation of ATSCs, cells
were cultured in the presence of FGF-2 and DEX, with or
without (control cells) selective Src family kinase inhibitors
(SU6656 and src kinase inhibitor I). The proliferation of
ATSCs in the presence of SU6656 (Fig. 6A) and src kinase
inhibitor I (Fig. 6B) was significantly decreased in a dose-
dependent manner as compared to control cells. These results
were consistent with the increased tyrosine phosphorylation
of Src by FGF-2 and DEX, and strongly suggested that the
stimulation of proliferation of ATSCs by FGF-2 and DEX
involves Src kinase.
Effect of Src kinase inhibitors on FGF-2 and
DEX–induced osteoblastic and adipogenic
differentiation of ATSCs
To determine whether the inhibition of Src kinase affected
osteoblastic and adipogenic differentiation, ATSCs were
cultured with FGF-2 and DEX in the presence or absence
FIG. 5. Protein phosphorylation in ATSCs expanded in the presence of FGF-2 and DEX. ATSCs were treated with FGF-2
plus DEX for 1, 3, or 5 days, and the levels of phosphorylation of JNK, ERK, Src, and p38 were analyzed by Western blot. The
phosphorylation of Src kinase was increased by FGF-2 and DEX.
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FIG. 6. Effect of Src family kinase
inhibitors (SU6656 and src kinase inhibitor I)
on FGF-2 and DEX–induced proliferation of
ATSCs. ATSCs were cultured with FGF-2
(1 ng=mL) plus DEX (10 nM) in the presence
or absence of the indicated concentrations
of SU6656 (A) or src kinase inhibitor I
(B) for 3, 5, or 7 days. Proliferation was
measured as described in Materials and
Methods. Data represents the means SE
(n¼ 3).
FIG. 7. Effect of SU6656 on FGF-2 and DEX–induced osteoblastic and adipogenic differentiation of ATSCs. ATSCs were
cultured with FGF-2 (1 ng=mL) plus DEX (10 nM) in the presence or absence of SU6656 (5 mM) for 5 days. Expanded cells were
reseeded and treated with either osteogenic or adipogenic medium. (A) Calcium deposition was assessed by staining with
AR-S solution (original magnification, 40). AR-S staining was quantified as described for Figure 3B (right panel). (B) Oil
droplets were visualized by staining with oil red O solution (original magnification, 40). (B) Oil red O staining was
quantified as described for Figure 4B (right panel). Color images available online at www.liebertonline.com=ten.
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(control cells) of SU6656, and then the expanded ATSCs
were cultured for an additional 14 days in osteogenic or
adipogenic medium. The osteoblastic differentiation of ATSCs
that were pretreated with SU6656 was decreased as compared
to control cells, based on AR-S staining. Similar results were
observed in two independent donor-derived ATSCs (Fig. 7A).
The level of adipogenic differentiation was also decreased by
SU6656, as assessed by oil red O staining (Fig. 7B). These
results suggested that Src kinase modulates the osteoblastic
and adipogenic differentiation potential of ATSCs.
Discussion
ATSCs have proven to be a useful source of cells for the
treatment of defective tissues by tissue engineering. How-
ever, to be useful for clinical applications, particularly for the
treatment of large lesions, it will be necessary to first expand
ATSCs in vitro. Previously, we and others have shown that
FGF-2 efficiently enhances the proliferation of BMSCs.9–11,23
A recent paper by Zaragosi et al. showed that FGF-2 plays a
critical role in the self-renewal of ATSCs.14 A low concen-
tration of FGF-2 may not induce chromosomal abnormality
in MSCs.24 Therefore, FGF-2 appears to be an essential
growth factor in the regulation of MSC proliferation and self-
renewal. Here, we investigated ways to enhance the growth
of ATSCs using a combination of FGF and steroids, and
found that FGF-2 in combination with BET or DEX sub-
stantially enhances the growth of ATSCs in vitro (Fig. 1). The
enhanced growth of ATSCs by FGF-2 and DEX was con-
firmed in ATSCs from three independent donors (Fig. 2).
Previous reports by us and others using BMSCs and ce-
mentoblasts have shown that a combination of FGF-2 and
DEX modulates the proliferation and biomineralization of
BMSCs. However, the underlying molecular mechanism of
this enhanced proliferation remains largely unknown.14,25,26
FGF-2 in combination with DEX enhanced the prolifera-
tion of ATSCs derived from three independent donors
(Fig. 2). Because FGF-2–induced proliferation was enhanced
by DEX, it is reasonable to hypothesize that FGF-2–induced
signaling pathways are potentiated by DEX, thus resulting in
enhanced ATSC proliferation. When we examined whether
DEX enhanced the expression of FGF receptors (FGFRs) as
a mechanism of amplification of FGF signaling, we found
that the expression levels of FGFRI, II, and IV were unaf-
fected by FGF-2 and DEX (Supplemental Fig. S1A, available
online at www.liebertonline.com=ten). Although FGFRIII
was induced by DEX, its expression was decreased by FGF-
2þDEX, suggesting that modulation of FGFRIII expression
may not contribute to the enhanced proliferation of ATSCs.
We also examined the phosphorylation levels of key signal-
ing molecules involved in cellular proliferation, such as JNK,
p38, ERK, and Src kinase. As shown in Figure 5, the levels of
phosphorylation of p38, ERK, and JNK were decreased by
treatment with FGF-2 and DEX, while the phosphorylation
of Src kinase was substantially increased. These results imply
that Src kinase plays a role in the stimulatory effect of FGF-2
and DEX on the proliferation of ATSCs. Subsequent analysis
of cell proliferation in the presence of inhibitors of Src kinase
confirmed that Src is involved in FGF-2 and DEX–induced
stimulation of ATSC proliferation (Figs. 6 and 7).
ATSCs that were expanded in the presence of FGF-2 and
DEX were able to differentiate into either osteoblasts or adi-
pocytes. Although we did not analyze the differentiation
of the expanded ATSCs along other lineages, these results
suggest that FGF-2 and DEX maintain or preserve the multi-
lineage potential of ATSCs that are expanded in vitro. Sig-
nificantly, ATSCs that were expanded in vitro with FGF-2 and
DEX exhibited a higher tendency to differentiate into both
osteoblasts and adipocytes. These results were in agreement
with previous reports in which a combination of FGF-2 and
DEX promoted the osteogenic commitment of BMSCs.18,19,27
In the current study, we also detected the expression of ALP in
cells that were treated with FGF-2 and DEX, which indicates
the commitment of ATSCs to an osteogenic lineage (Supple-
mental Fig. S1B). Treatment with FGF-2 plus DEX also pro-
moted the commitment of ATSCs to the adipogenic lineage.
The mRNA levels of PPARg2, which plays an important role
in adipocyte differentiation, were increased in cells cultured
with FGF-2 and DEX for 5 days (Supplemental Fig. S1B).
Thus, FGF-2 and DEX increased the osteogenic potential, as
well as the adipogenic potential of ATSCs.
The inhibition of Src kinase resulted in the suppression of
osteoblastic and adipogenic differentiation in ATSCs (Figs. 6
and 7). The tyrosine phosphorylation of Src kinase increased
during FGF-2 and DEX–induced proliferation of ATSCs (Fig. 5),
and treatment with inhibitors of Src family kinases suppressed
the proliferation of ATSCs (Fig. 6). These results suggest that
the osteogenic and adipogenic differentiation of ATSCs is
modulated by the proliferative capacity of the cells. In fact,
when the number of cells that were incubated in osteogenic
medium was increased, we observed an enhancement of dif-
ferentiation of ATSCs along the osteoblastic lineage (Supple-
mental Fig. S2, available online at www.liebertonline.com=
ten). These results suggest that the inhibition of Src kinase
causes the suppression of cell growth and subsequent differ-
entiation of ATSCs along the osteoblastic or adipocytic lineage.
In summary, we have demonstrated that treatment of
ATSCs with a combination of FGF-2 and DEX is an efficient
method for expanding these cells in vitro and, importantly,
can preserve the osteogenic and adipogenic potential of the
cells. We also demonstrated that Src kinase is involved in the
stimulation of proliferation of ATSCs.
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